Format

Send to

Choose Destination
Ann Oncol. 2017 Feb 1;28(2):305-312. doi: 10.1093/annonc/mdw622.

Do all patients with advanced HER2 positive breast cancer need upfront-chemo when receiving trastuzumab? Randomized phase III trial SAKK 22/99.

Author information

1
Institute of Oncology and Breast Unit of Southern Switzerland, Bellinzona.
2
Swiss Group for Clinical Cancer Research, Coordinating Center, Bern.
3
Breast Center, St. Gallen, Switzerland.
4
European Institute of Oncology, Milano, Italy.
5
Molecular Pathology, University Hospital, Basel.
6
Pathology, Kantonsspital, San Gallen.
7
International Breast Cancer Study Group Coordinating Center, Bern.
8
Department of Internal Medicine, Kantonsspital, St.Gallen.
9
Oncology, Kantonsspital, Aarau, Switzerland.
10
Oncology, University Hospital, Zurich.
11
Breast Unit, Inselspital, Bern.
12
Medical Oncology, Inselspital Bern, now at Luzerner Kantonsspital.
13
Oncology, University Hospital, Basel.
14
Breast Center, St.Gallen.
15
Department of Medicine, Kantonsspital, Chur.
16
Breast Centre, University Hospital, Lausanne, Switzerland.

Abstract

Background:

HER2-targeted therapy plus chemotherapy is standard treatment in advanced HER2+ breast cancer. Trastuzumab alone followed by addition of chemotherapy at disease progression versus upfront combination therapy has not been elucidated.

Patients and methods:

One-hundred seventy-five patients with measurable/evaluable HER2+ advanced disease without previous HER2-directed therapy were randomized to trastuzumab alone followed, at disease progression, by the combination with chemotherapy (Arm A) or upfront trastuzumab plus chemotherapy (Arm B). Chemotherapy could be stopped after ≥6 cycles in responding patients, trastuzumab was continued until progression. The primary endpoint of this superiority trial was time to progression (TTP) on combined trastuzumab-chemotherapy (Combination-TTP) in both arms. Secondary endpoints included response rate, TTP, overall survival, quality of life and toxicity.

Results:

Combination-TTP was longer than expected in both arms, 12.2 months in Arm A and 10.3 months in Arm B and not significantly different (hazard ratio [HR] 0.7; 95% CI 0.5-1.1; P =0.1). Overall survival was also not significantly different (HR 0.9; 95% CI 0.6-1.5; P = 0.55). In Arm A, the median TTP before introduction of chemotherapy was 3.7 months (95% CI 2.3-5.4), yet at 2 years 6% of patients were still on trastuzumab alone. Patients without visceral disease had a Combination-TTP of 21.8 months in arm A, compared with 10.1 months in arm B (unplanned analysis HR 2.1, 95% CI 1.1-4.2, P = 0.03). Patients with visceral disease showed no difference. Toxicity was chemotherapy-related.

Conclusion:

The outcome of patients receiving sequential trastuzumab-chemotherapy or upfront combination was similar. We failed to demonstrate superiority of the sequential approach. These results nevertheless suggest chemotherapy and its toxicity can be deferred, especially in patients with indolent, non-visceral disease. Despite a larger non-inferiority confirmatory study would be needed, these findings represent an additional proof of concept that de-escalation strategies can be discussed in individual patients.

KEYWORDS:

HER2+; advanced breast cancer; breast cancer; chemotherapy; combination therapy; sequential therapy; trastuzumab

PMID:
27998961
DOI:
10.1093/annonc/mdw622
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center